Micro-dosing GLP-1/GIP RA in ME/CFS & Long Covid. Clinician's Roundtable with Drs. Kaufman & Dempsey

Renegade Research Clinician's Roundtable with David Kaufman, MD, and Tania Dempsey, MD, sharing clinical experience in using small doses of GLP1/GIP Receptor Agonists in ME/CFS and Long Covid. 0:00:00 Opening of Zoom Room 0:00:28 Welcome and Announcements 0:02:10 Dr. Kaufman and Dr. Dempsey Discuss GLP-1/GIP RA including tirzepatide and semaglutide 0:13:10 Q. Any similarities in the patients that are responding?  0:26:12 How do you make the decision to prescribe this medication and the dose? 0:48:45 Stuart Malcolm, MD, joins the discussion 0:57:40 What would you say to clinicians who want to learn to use these meds with pts 1:03:17 Audience Q&A 1:03:23 Use under age 18? 1:05:06 Increase in Appetite? 1:08:39 Any identifying predictors of  + or - responses? 1:21:02 Will RECOVER TLC clinical trial use micro or standard dose  GLP-1  1:23:24 How decide which drug to start with a particular patient? 1:30:00 Close This roundtable was covered by CortJohnson in a Health Rising post on Nov 3, 2025: "The GLP-1 Agonist Boom in ME/CFS, FM and Long COVID: Insights, Using it, Trials Underway" https://healthrising.org/blog/2025/11... Announcements for this event with speaker info, links to their previous roundtables, and more https://docs.google.com/document/d/1q... To sign up for Renegade Research newsletter, go to https://renegade-research.org/join-em...